发明授权
US08383793B2 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
有权
用于诊断和治疗抗间变性淋巴瘤激酶（ALK）激酶抑制剂的癌症的方法和组合物
- 专利标题： Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
- 专利标题（中）： 用于诊断和治疗抗间变性淋巴瘤激酶（ALK）激酶抑制剂的癌症的方法和组合物
-
申请号： US12761050申请日： 2010-04-15
-
公开(公告)号： US08383793B2公开(公告)日： 2013-02-26
- 发明人: Stephan W. Morris , Qin Jiang , Xiaoli Cui , Liquan Xue
- 申请人： Stephan W. Morris , Qin Jiang , Xiaoli Cui , Liquan Xue
- 申请人地址： US TN Memphis
- 专利权人： St. Jude Children's Research Hospital
- 当前专利权人： St. Jude Children's Research Hospital
- 当前专利权人地址： US TN Memphis
- 代理机构： Ballard Spahr LLP
- 主分类号： C07H21/04
- IPC分类号： C07H21/04 ; C12N15/00
摘要：
Compositions and methods for the diagnosis and treatment of a cancer that is resistant to at least one anaplastic lymphoma kinase (ALK) kinase inhibitor are provided herein. The present invention is based on the discovery of mutations within ALK that confer resistance to at least one ALK kinase inhibitor. Polynucleotides and polypeptides having at least one ALK inhibitor resistance mutation are provided and find use in methods and compositions useful in the diagnosis, prognosis, and/or treatment of diseases associated with aberrant ALK activity, more particularly, those that are resistant to at least one ALK kinase inhibitors. Methods and compositions are also provided for the identification of agents that can inhibit the kinase activity and/or reduce the expression level of the ALK resistance mutants.
公开/授权文献
信息查询
